Skip to content
Combined Shape Created with Sketch.
  • EyewireTV
  • Stocks
  • Interests
    • Cataract and Refractive Eye-Grey Created with Sketch.
    • Glaucoma Gauge-Grey Created with Sketch.
    • Healthcare Cross-Grey Created with Sketch.
    • Optometry Laser-Grey Created with Sketch.
    • Product Approvals Gear-Grey Created with Sketch.
    • Retina Laser-Grey Created with Sketch.
  • More
    • Events
    • About
    • Send a Tip
    • Advertising
    • Privacy Policy
  • EyewireTV
  • Stocks
  • Interests
    • Cataract and Refractive Eye-Grey Created with Sketch.
    • Glaucoma Gauge-Grey Created with Sketch.
    • Healthcare Cross-Grey Created with Sketch.
    • Optometry Laser-Grey Created with Sketch.
    • Product Approvals Gear-Grey Created with Sketch.
    • Retina Laser-Grey Created with Sketch.
  • Events
  • About
  • Send a Tip
  • Advertising
  • Privacy Policy

Regeneron

02.07.19

Regeneron Q4 Earnings & Sales Beat on Strong Eylea Sales

Source: Nasdaq

09.13.18

FDA to Review Eylea (Aflibercept) Injection for the Treatment of Diabetic Retinopathy

Source: Regeneron Pharmaceuticals

08.17.18

FDA Approves 12-Week Dosing for Eylea in Wet AMD Patients

Source: Regeneron Pharmaceuticals

08.14.18

Regeneron Faces Delay to FDA Approval of 12-Week Dosing Schedule for Eylea in Wet AMD

Source: FirstWord

05.04.18

US Sales of Eylea in First Quarter Best Estimates

Source: FirstWord

View more stories

Home

Menu

Share

  • Cataract and Refractive
  • Glaucoma
  • Healthcare
  • Optometry
  • Product Approvals
  • Retina
  • Events
  • About
  • Send a Tip
  • Advertising
  • Contact
  • EyewireTV
  • Stocks
  • Privacy Policy
Created with Sketch. Created with Sketch. Created with Sketch. Created with Sketch.
eyewire-news-color bmc-mark Created with Sketch.

© 2019 Bryn Mawr Communications, LLC.

All Rights Reserved.